| Species |
Human |
| Protein Construction |
FGF8a (Gln23-Arg204)
Accession # P55075-2 |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 0.01EU per μg by the LAL method. |
| Biological Activity |
Measured in a cell proliferation assay using Balb/c 3T3 mouse fibroblasts. The ED50 for this effect is 0.5 2 μg/mL. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
21.20 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 21.20 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 20mM Tris-HCl, 300mM NaCl (pH 8.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Two of the four human FGF8 splice isoforms, FGF8a and FGF8b, are expressed in the mid-hindbrain region during development. Although the only difference between these isoforms is the presence of an additional 11 amino acids at the N terminus of FGF8b, these isoforms possess remarkably different abilities to pattern the midbrain and anterior hindbrain. |
| Synonyms |
FGF8a; FGF-8a; FGF-8; FGF8; FGF 8; AIGF; HBGF-8; HBGF8; HBGF 8; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
